Net Income (Loss) Attributable to Parent in USD of Allogene Therapeutics, Inc. from Q4 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Allogene Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q4 2017 to Q3 2025.
  • Allogene Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$41.4M, a 37.6% increase year-over-year.
  • Allogene Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$212M, a 25.2% increase year-over-year.
  • Allogene Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$258M, a 21.3% increase from 2023.
  • Allogene Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$327M, a 3.86% increase from 2022.
  • Allogene Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$340M, a 87% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Allogene Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$212M -$41.4M +$24.9M +37.6% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 -$237M -$50.9M +$15.4M +23.2% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-06
Q1 2025 -$252M -$59.7M +$5.27M +8.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-06
Q4 2024 -$258M -$59.9M +$25.8M +30.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-13
Q3 2024 -$283M -$66.3M -$4.01M -6.43% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 -$279M -$66.4M +$12.9M +16.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-06
Q1 2024 -$292M -$65M +$35M +35% Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-06
Q4 2023 -$327M -$85.8M +$11.5M +11.8% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-13
Q3 2023 -$339M -$62.3M +$22M +26.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$361M -$79.2M +$1.06M +1.32% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$362M -$100M -$21.4M -27.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$340M -$97.3M -$97.4M -113210% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$243M -$84.2M -$6.06M -7.75% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-14
Q2 2022 -$237M -$80.3M -$9.35M -13.2% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-14
Q1 2022 -$228M -$78.6M -$45.6M -138% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-14
Q4 2021 -$182M $86K +$135M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 -$317M -$78.2M -$12M -18.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$305M -$70.9M -$9.96M -16.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-02
Q1 2021 -$295M -$33M +$21.5M +39.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-02
Q4 2020 -$316M -$135M -$73.7M -121% Oct 1, 2020 Dec 31, 2020 10-K/A 2024-03-14
Q3 2020 -$243M -$66.2M -$15.5M -30.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$227M -$61M -$19.7M -47.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$207M -$54.5M -$22.9M -72.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$185M -$61M -$30.5M -100% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-27
Q3 2019 -$154M -$50.7M -$7.24M -16.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$147M -$41.2M +$93.7M +69.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$240M -$31.6M -$29M -1116% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 -$212M -$30.5M -$30.5M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$181M -$43.5M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$135M Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$2.6M Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$2K* Nov 30, 2017 Dec 31, 2017 10-K 2020-02-27

Allogene Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$258M +$69.7M +21.3% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 -$327M +$13.1M +3.86% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
2022 -$340M -$158M -87% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 -$182M +$134M +42.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-14
2020 -$316M -$132M -71.4% Jan 1, 2020 Dec 31, 2020 10-K/A 2024-03-14
2019 -$185M +$26.9M +12.7% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-23
2018 -$212M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.